共 50 条
- [1] A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors[J]. CANCER RESEARCH, 2019, 79 (13)Falchook, Gerald S.论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst HealthONE, Denver, CO USA Sarah Cannon Res Inst HealthONE, Denver, CO USASachdev, Jasgit论文数: 0 引用数: 0 h-index: 0机构: HonorHlth Res Inst, Scottsdale, AZ USA Sarah Cannon Res Inst HealthONE, Denver, CO USAImedio, Esteban Rodrigo论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Cambridge, England Sarah Cannon Res Inst HealthONE, Denver, CO USAKumar, Sanjeev论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Cambridge, England Sarah Cannon Res Inst HealthONE, Denver, CO USAMugundu, Ganesh论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Quantitat Clin Pharmacol, IMED Biotech Unit, Boston, MA USA Sarah Cannon Res Inst HealthONE, Denver, CO USAChmielecki, Juliann论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Translat Sci, IMED Biotech Unit, Oncol, Waltham, MA USA Sarah Cannon Res Inst HealthONE, Denver, CO USAJones, Suzanne论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA Sarah Cannon Res Inst HealthONE, Denver, CO USASpigel, David R.论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA Tennessee Oncol, Nashville, TN USA Sarah Cannon Res Inst HealthONE, Denver, CO USAJohnson, Melissa论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA Tennessee Oncol, Nashville, TN USA Sarah Cannon Res Inst HealthONE, Denver, CO USA
- [2] First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours[J]. ANNALS OF ONCOLOGY, 2020, 31 : S501 - S502Gelderblom, H.论文数: 0 引用数: 0 h-index: 0机构: Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, Netherlands Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsGietema, J. A.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Groningen UMCG, Med Oncol, Groningen, Netherlands Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsDesar, I. M. E.论文数: 0 引用数: 0 h-index: 0机构: Radboud Univ Nijmegen, Med Ctr Nijmegen Undo, Med Oncol Dept, Nijmegen, Netherlands Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsAjmone, N. M.论文数: 0 引用数: 0 h-index: 0机构: Leids Univ Med Ctr LUMC, Cardiol, Leiden, Netherlands Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsJalving, M.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Groningen UMCG, Med Oncol Dept, Groningen, Netherlands Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsKroep, J. R.论文数: 0 引用数: 0 h-index: 0机构: Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, Netherlands Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsNicolas, V.论文数: 0 引用数: 0 h-index: 0机构: Debiopharm Int SA, Clin Res Dept, Lausanne, Switzerland Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsVaslin, A.论文数: 0 引用数: 0 h-index: 0机构: Debiopharm Int SA, Clin Res Dept, Lausanne, Switzerland Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsTobal, K.论文数: 0 引用数: 0 h-index: 0机构: Debiopharm Int SA, Clin Res Dept, Lausanne, Switzerland Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsPurcea, D.论文数: 0 引用数: 0 h-index: 0机构: Debiopharm Int SA, Biostat, Lausanne, Switzerland Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, Netherlandsvan Haren, S. F.论文数: 0 引用数: 0 h-index: 0机构: Debiopharm Int SA, Clin Res Dept, Lausanne, Switzerland Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, NetherlandsDamstrup, L.论文数: 0 引用数: 0 h-index: 0机构: Debiopharm Int SA, Clin Res Dept, Lausanne, Switzerland Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, Netherlands
- [3] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors[J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 493 - 502Falchook, Gerald S.论文数: 0 引用数: 0 h-index: 0机构: HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USA HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USASachdev, Jasgit论文数: 0 引用数: 0 h-index: 0机构: HonorHealth Res Inst, Scottsdale, AZ USA HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USAImedio, Esteban Rodrigo论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Oncol R&D, Cambridge, England HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USAKumar, Sanjeev论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Oncol R&D, Cambridge, England HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USAMugundu, Ganesh M.论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, CPSS, Boston, MA USA HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USAJenkins, Suzanne论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Oncol R&D, Cambridge, England HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USAChmielecki, Juliann论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Translat Med Early Res & Dev, Boston, MA USA HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USAJones, Suzanne论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USASpigel, David R.论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA Tennessee Oncol, Nashville, TN USA HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USAJohnson, Melissa论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA Tennessee Oncol, Nashville, TN USA HealthONE, Sarah Cannon Res Inst, Denver, CO 80218 USA
- [4] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors[J]. Investigational New Drugs, 2023, 41 : 493 - 502Gerald S Falchook论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DJasgit Sachdev论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DEsteban Rodrigo Imedio论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DSanjeev Kumar论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DGanesh M Mugundu论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DSuzanne Jenkins论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DJuliann Chmielecki论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DSuzanne Jones论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DDavid R Spigel论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&DMelissa Johnson论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Research Institute at HealthONE,Oncology R&D
- [5] The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase lb study[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Bang, Yung-Jue论文数: 0 引用数: 0 h-index: 0机构: Seoul Natl Univ Hosp, Seoul, South Korea Seoul Natl Univ Hosp, Seoul, South KoreaDe Souza, Paul论文数: 0 引用数: 0 h-index: 0机构: Liverpool Hosp, Liverpool, Australia Seoul Natl Univ Hosp, Seoul, South KoreaKim, Sang-We论文数: 0 引用数: 0 h-index: 0机构: Asan Med Ctr, Seoul, South Korea Seoul Natl Univ Hosp, Seoul, South KoreaLickliter, Jason论文数: 0 引用数: 0 h-index: 0机构: Nucleus Network Ltd, Melbourne, Vic, Australia Seoul Natl Univ Hosp, Seoul, South KoreaNaito, Yoichi论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan Seoul Natl Univ Hosp, Seoul, South KoreaPark, Keunchil论文数: 0 引用数: 0 h-index: 0机构: Samsung Med Ctr, Seoul, South Korea Seoul Natl Univ Hosp, Seoul, South KoreaKumar, Sanjeev论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Cambridge, England Seoul Natl Univ Hosp, Seoul, South KoreaMugundu, Ganesh M.论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Waltham, MA USA Seoul Natl Univ Hosp, Seoul, South KoreaKato, Hidenori论文数: 0 引用数: 0 h-index: 0机构: Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan Seoul Natl Univ Hosp, Seoul, South Korea
- [6] A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Lin, Chia-Chi论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanGrewal, Jaspreet Singh论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanSommerhalder, David论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanStrauss, James Fredric论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanBai, Li-Yuan论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanShen, Lin论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanYeh, Yu-Min论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanHsieh, Chih-Yi论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanCai, Sui Xiong论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanTian, Ye Edward论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanXia, Huan论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanZhang, Congcong论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanLi, Baoyue论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanZhang, Ming论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanMa, Ning论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanZhao, Liping论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanMa, Jie论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanShi, Huiyan论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, TaiwanYu, Zhixin论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
- [7] Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1725 - +Fu, Siqing论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Unit 0455,1515 Holcombe Blvd, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAYao, Shuyang论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAYuan, Yuan论文数: 0 引用数: 0 h-index: 0机构: City Hope Comprehens Canc Ctr, Duarte, CA USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAPrevis, Rebecca A.论文数: 0 引用数: 0 h-index: 0机构: Duke Univ, Med Ctr, Durham, NC USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAElias, Anthony D.论文数: 0 引用数: 0 h-index: 0机构: Univ Colorado, Canc Ctr, Aurora, CO USA Univ Texas MD Anderson Canc Ctr, Houston, TX USACarvajal, Richard D.论文数: 0 引用数: 0 h-index: 0机构: Columbia Univ, Med Ctr, New York, NY USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAGeorge, Thomas J.论文数: 0 引用数: 0 h-index: 0机构: Univ Florida, Hlth Canc Ctr, Gainesville, FL USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAYuan, Ying论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAYu, Lihou论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAWestin, Shannon N.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAXing, Yan论文数: 0 引用数: 0 h-index: 0机构: City Hope Comprehens Canc Ctr, Duarte, CA USA Univ Texas MD Anderson Canc Ctr, Houston, TX USADumbrava, Ecaterina E.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAKarp, Daniel D.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAPiha-Paul, Sarina A.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USATsimberidou, Apostolia M.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAAhnert, Jordi Rodon论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USATakebe, Naoko论文数: 0 引用数: 0 h-index: 0机构: NCI, Div Canc Treatment & Diag, Bethesda, MD USA Univ Texas MD Anderson Canc Ctr, Houston, TX USALu, Karen论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAKeyomarsi, Khandan论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USAMeric-Bernstam, Funda论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX USA
- [8] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors[J]. Investigational New Drugs, 2019, 37 : 674 - 683Elena Elez论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Carlos Gomez-Roca论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Arturo Soto Matos-Pita论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Guillem Argiles论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Thibaud Valentin论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Cinthya Coronado论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Jorge Iglesias论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Teresa Macarulla论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Sarah Betrian论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Salvador Fudio论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Katrin Zaragoza论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Josep Tabernero论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)Jean-Pierre Delord论文数: 0 引用数: 0 h-index: 0机构: Universitat Autònoma de Barcelona,Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)
- [9] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors[J]. INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683Elez, Elena论文数: 0 引用数: 0 h-index: 0机构: Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain Univ Autonoma Barcelona, VHIO, Barcelona, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainGomez-Roca, Carlos论文数: 0 引用数: 0 h-index: 0机构: IUCT Oncopole, Inst Claudius Regaud, Clin Res Unit, 1 Ave Joliot Curie, F-31059 Toulouse, France Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainSoto Matos-Pita, Arturo论文数: 0 引用数: 0 h-index: 0机构: Pharma Mar SA, Clin R&D, Madrid, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainArgiles, Guillem论文数: 0 引用数: 0 h-index: 0机构: Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain Univ Autonoma Barcelona, VHIO, Barcelona, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainValentin, Thibaud论文数: 0 引用数: 0 h-index: 0机构: IUCT Oncopole, Inst Claudius Regaud, Clin Res Unit, 1 Ave Joliot Curie, F-31059 Toulouse, France Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainCoronado, Cinthya论文数: 0 引用数: 0 h-index: 0机构: Pharma Mar SA, Clin R&D, Madrid, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainIglesias, Jorge论文数: 0 引用数: 0 h-index: 0机构: Pharma Mar SA, Clin R&D, Madrid, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainMacarulla, Teresa论文数: 0 引用数: 0 h-index: 0机构: Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain Univ Autonoma Barcelona, VHIO, Barcelona, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainBetrian, Sarah论文数: 0 引用数: 0 h-index: 0机构: IUCT Oncopole, Inst Claudius Regaud, Clin Res Unit, 1 Ave Joliot Curie, F-31059 Toulouse, France Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainFudio, Salvador论文数: 0 引用数: 0 h-index: 0机构: Pharma Mar SA, Clin R&D, Madrid, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainZaragoza, Katrin论文数: 0 引用数: 0 h-index: 0机构: Pharma Mar SA, Clin R&D, Madrid, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainTabernero, Josep论文数: 0 引用数: 0 h-index: 0机构: Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain Univ Autonoma Barcelona, VHIO, Barcelona, Spain Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, SpainDelord, Jean-Pierre论文数: 0 引用数: 0 h-index: 0机构: IUCT Oncopole, Inst Claudius Regaud, Clin Res Unit, 1 Ave Joliot Curie, F-31059 Toulouse, France Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain
- [10] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors[J]. INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 990 - 1000Bauer, Todd论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USACho, Byong Chul论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ, Coll Med, Seoul, South Korea Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAHeist, Rebecca论文数: 0 引用数: 0 h-index: 0机构: Massachusetts Gen Hosp, Boston, MA 02114 USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USABazhenova, Lyudmila论文数: 0 引用数: 0 h-index: 0机构: Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAWerner, Theresa论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAGoel, Sanjay论文数: 0 引用数: 0 h-index: 0机构: Albert Einstein Coll Med, Montefiore Med Ctr, New York, NY USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAKim, Dong-Wan论文数: 0 引用数: 0 h-index: 0机构: Seoul Natl Univ, Coll Med, Seoul, South Korea Seoul Natl Univ Hosp, Seoul, South Korea Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAAdkins, Douglas论文数: 0 引用数: 0 h-index: 0机构: Washington Univ, St Louis, MO 63110 USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USACarvajal, Richard D.论文数: 0 引用数: 0 h-index: 0机构: Columbia Univ, Irving Med Ctr, New York, NY USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAAlva, Ajjai论文数: 0 引用数: 0 h-index: 0机构: Univ Michigan, Med Ctr, Ann Arbor, MI USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAEaton, Keith论文数: 0 引用数: 0 h-index: 0机构: Univ Washington, Seattle, WA 98195 USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAWang, Judy论文数: 0 引用数: 0 h-index: 0机构: Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USALiu, Yong论文数: 0 引用数: 0 h-index: 0机构: Mirati Therapeut Inc, San Diego, CA USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAYan, Xiaohong论文数: 0 引用数: 0 h-index: 0机构: Mirati Therapeut Inc, San Diego, CA USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAChristensen, Jamie论文数: 0 引用数: 0 h-index: 0机构: Mirati Therapeut Inc, San Diego, CA USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USANeuteboom, Saskia论文数: 0 引用数: 0 h-index: 0机构: Mirati Therapeut Inc, San Diego, CA USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAChao, Richard论文数: 0 引用数: 0 h-index: 0机构: Mirati Therapeut Inc, San Diego, CA USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USAPant, Shubham论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA Sarah Cannon Res Inst, Tennessee Oncol, Dept Drug Dev, 250 25th Ave North,Ste 100, Nashville, TN 37203 USA